CONTENTS

1. INTRODUCTION

1.1. Reproductive Tract Infections (RTIs) 1

1.2. Types of Reproductive Tract Infections 2

1.2.1. Endogenous Infections

1.2.2. Iatrogenic Infections

1.2.3. Sexually Transmitted Infections

1.3. Microbiology of Reproductive Tract Infections 3

1.4. Reproductive Tract Infection Caused by Fungi and Bacteria 4

1.4.1. Fungal Reproductive Tract Infection – Candida

1.4.2. Historical Perspective of Candida

1.4.2.1. Classification of Yeast Candida

1.4.3. Pathogenic Mechanism and Virulence Factors of Candida

1.4.3.1. Biofilm Formation

1.4.3.2. Secretrated Aspartyl Proteinase

1.4.3.3. Phospholipase

1.4.3.4. Sensitivity to hydrogen peroxide

1.4.3.5. Hemolytic property

1.4.4. Pathology of Candida

1.4.5. Clinical manifestations of Candida

1.4.6. Epidemiology of Candidiasis

1.4.6.1. Global Scenario

1.4.6.2. Indian Scenario

1.4.7. Problems faced with Vulvovaginal Candidiasis

1.4.8. Factors influencing Vulvovaginal Candidiasis

1.4.9. Laboratory diagnosis of Vulvovaginal Candidiasis
1.4.10. Prevention and Treatment of Candidiasis

1.4.11. Antifungal resistance in Candida

1.4.12. Molecular mechanism of drug resistance in Candida

1.5. Reproductive tract infections caused by Bacteria

1.5.1. Bacterial reproductive tract infection- Neisseria gonorrhoeae

1.5.2. Gonorrhoea: A Historical perspective

1.5.3. Pathogenesis and virulence factors of Neisseria gonorrhoeae

1.5.3.1. Pili

1.5.3.2. Opa Proteins

1.5.3.3. Lipooligosaccharide

1.5.3.4. Porin

1.5.4. Pathology of gonorrhoea among genders

1.5.4.1. In men

1.5.4.2. In women

1.5.5. Clinical manifestations of gonorrhoea

1.5.6. Epidemiology of gonorrhoea

1.5.6.1. Global Scenario

1.5.6.2. Indian Scenario

1.5.7. Problems faced with gonorrhoea

1.5.8. Factors influencing gonococcal infection

1.5.9. Laboratory diagnosis of gonorrhoea

1.5.10. Prevention and treatment of gonorrhoea

1.5.11. Antibacterial resistance in Neisseria gonorrhoeae

1.5.12. Molecular mechanism of drug resistance in Neisseria gonorrhoeae

1.6. Need of Research
2. REVIEW OF LITERATURE

2.1. Reproductive tract Infections

2.2. Prevalence of *Candida* spp
   
   2.2.1. Global Prevalence
   
   2.2.2. Prevalence in India
   
   2.2.3. Prevalence in Tamil Nadu

2.3. Prevalence of *Neisseria gonorrhoeae*
   
   2.3.1. Global Prevalence
   
   2.3.2. Prevalence in India
   
   2.3.3. Prevalence in Tamil Nadu

2.4. Risk factors associated with reproductive tract infection
   
   2.4.1. Candidiasis
   
   2.4.2. Gonorrhoea

2.5. Socio demographic characteristics and symptoms associated with RTIS

2.6. Virulence factors influencing the pathogenesis of microbes
   
   2.6.1. Virulence factors of *Candida* spp
   
   2.6.2. Virulence factors of *Neisseria gonorrhoeae*

2.7. Drug resistance in *Candida* spp
   
   2.7.1. Global Scenario
   
   2.7.2. Indian Scenario

2.8. Drug resistance in *Neisseria gonorrhoea*
   
   2.8.1. Global Scenario
   
   2.8.2. Indian Scenario

2.9. Molecular characteristics of drug resistance in *Candida* spp
2.10. Molecular characteristics of drug resistance in *Neisseria gonorrhoeae* 60

2.10.1. Plasmid mediated resistance

2.10.2. Chromosomal mediated resistance

2.11. Diagnosis and control of RTIS 63

3. MATERIALS AND METHODS

3.1. Sampling Area 67

3.2. Study Population 67

3.3. Data Collection 67

3.4. Data Analysis 68

3.5. Ethical Approval 68

3.6. Collection and processing of vaginal samples 68

3.6.1. Characterization of *Candida* spp

3.7. Collection and processing of cervical samples 69

3.7.1. Characterization of *Neisseria gonorrhoeae*

3.8. Antifungal susceptibility test for *Candida* spp 70

3.9. Antimicrobial susceptibility test for *Neisseria gonorrhoeae* 71

3.10. Demonstration of virulence factors of *Candida* spp. 72

3.10.1. Biofilm formation

3.10.2. Phospholipase Estimation

3.10.3 Proteinase Detection

3.10.4. Hydrogen Peroxide Sensitivity

3.10.5. Hemolytic Property

3.11. Identification of drug resistance gene in *Candida albicans* by PCR 75

3.11.1. Isolation of genomic DNA
3.11.2. Confirmation of DNA by agarose gel electrophoresis
3.11.3. Polymerase chain reaction (PCR)

3.12. Molecular identification of *Candida albicans* by (28S ribosomal RNA) sequencing
3.12.1. Polymerase Chain Reaction
3.12.2. Elution and purification of amplified DNA
3.12.3. Similarity searching of 28S rRNA

3.13. PCR for the Detection of Plasmid Borne Drug Resistance in *Neisseria gonorrhoeae*
3.13.1. Extraction of DNA by boiling method
3.13.2. Detection of PPNG plasmid by PCR
3.13.3. Detection of TRNG plasmid by PCR
3.13.4. Visualization of plasmid DNA by Agarose Gel Electrophoresis

3.14. Molecular identification of *Neisseria gonorrhoeae* by *tbpB* gene sequencing
3.14.1. Primary PCR of DNA extract for *tbpB* gene
3.14.2. Sequencing of *tbpB* gene of *Neisseria gonorrhoeae*
3.14.3. Similarity searching of *tbpB* gene of *Neisseria gonorrhoeae*

4. 4. RESULTS AND DISCUSSION

4.1. Isolation and identification of *Candida* spp and *Neisseria gonorrhoeae* from women attending ICTC Clinic.
4.1.1. Isolation of *Candida* spp from women attending the ICTC Clinic
4.1.1.1. Characterization of *Candida* spp by carbohydrate assimilation tests
4.1.2. Isolation and characterization of *Neisseria gonorrhoeae* from women attending the ICTC Clinic

4.2. Prevalence of *Candida* spp and *Neisseria gonorrhoeae* from women attending the ICTC Clinic
4.2.1. Prevalence of *Candida* spp from women attending the ICTC Clinic

4.2.1.1. Prevalence of *Candida albicans* and non-albicans *Candida* isolated from ICTC patients

4.2.1.2. Age distribution of *Candida* spp among the women attending the ICTC Clinic

4.2.1.3. Association of candidiasis among various socio demographic factors, symptoms and risk factors in women attending the ICTC Clinic

4.2.2. Prevalence of *Neisseria gonorrhoeae* among the women attending the ICTC Clinic

4.2.2.1. Age wise distribution of *Neisseria gonorrhoeae* among the women attending the ICTC Clinic

4.2.2.2. Association of *Neisseria gonorrhoeae* with the socio demographic factors, symptoms and risk factors among the women attending the ICTC Clinic

4.2.3. Co-infection of *Neisseria gonorrhoeae* with *Candida* spp isolated from women attending ICTC Clinic

4.3. Antibiogram of *Candida* spp and *Neisseria gonorrhoeae* isolated from women attending the ICTC Clinic

4.3.1. Antifungal susceptibility pattern of *Candida* spp isolated from the women attending ICTC Clinic

4.3.2. Antibacterial susceptibility pattern of *Neisseria gonorrhoeae* isolated from the women attending ICTC Clinic

4.4. Identification of virulence factors of *Candida* spp

4.4.1. Formation of Biofilm by clinical isolates of *Candida* spp

4.4.2. Secretory Aspartyl Proteinase production by clinical isolates of *Candida* spp

4.4.3. Phospholipase production by *Candida* spp

4.4.4. Sensitivity/Resistant pattern of *Candida* spp against Hydrogen Peroxide (H$_2$O$_2$)
4.4.5. Haemolytic activity exhibited by Candida species isolated from ICTC Clinic

4.5. Identification and characterization of azole resistance gene in Candida spp

4.6. PCR amplification of 28SrRNA gene for MDR Candida albicans

4.6.1. Blast Analysis of 28SrRNA gene sequence of Candida albicans

4.7. Determination of plasmid mediated resistance for Neisseria gonorrhoeae

4.8. PCR Amplification of tbpB gene for Neisseria gonorrhoeae

4.8.1. Blast Analysis of Quinolone resistant tbpB gene sequence of Neisseria gonorrhoeae

5. SUMMARY AND CONCLUSION

BIBLIOGRAPHY

ANNEXURE

Publications
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Phenotypic characteristics of <em>Candida</em> spp isolated from women of ICTC Clinic.</td>
</tr>
<tr>
<td>2</td>
<td>Assimilation of carbohydrates by <em>Candida</em> spp isolated from ICTC patients.</td>
</tr>
<tr>
<td>3</td>
<td>Phenotypic characteristics of <em>Neisseria gonorrhoeae</em> isolated from ICTC Patients.</td>
</tr>
<tr>
<td>4</td>
<td>Species distribution of <em>Candida</em> isolates from vaginal samples of females visiting ICTC Clinic.</td>
</tr>
<tr>
<td>5</td>
<td>Socio demographic factors of reproductive tract infections among females with vulvovaginal Candidiasis.</td>
</tr>
<tr>
<td>6</td>
<td>Associated Symptoms with vulvovaginal Candidiasis among females attending ICTC Clinic.</td>
</tr>
<tr>
<td>7</td>
<td>Risk factors associated with females suffered from vulvovaginal candidiasis.</td>
</tr>
<tr>
<td>8</td>
<td>Socio demographic factors associated with women infected with Gonococci.</td>
</tr>
<tr>
<td>9</td>
<td>Symptoms associated with gonorrhoea positive females attending ICTC Clinic.</td>
</tr>
<tr>
<td>10</td>
<td>Risk factors associated with gonorrhoea positive females attending ICTC Clinic.</td>
</tr>
<tr>
<td>11</td>
<td>Co-infection of <em>Neisseria gonorrhoeae</em> with <em>Candida</em> spp.</td>
</tr>
<tr>
<td>12</td>
<td>Antifungal susceptibility pattern demonstrated by the isolates of <em>Candida</em> spp.</td>
</tr>
<tr>
<td>13</td>
<td>Mean and standard error for the isolates of <em>Candida</em> spp.</td>
</tr>
<tr>
<td>14</td>
<td>Antibiogram-Resistogram pattern of <em>Neisseria gonorrhoeae</em> isolates obtained from gonorrhoeal patients attending ICTC Clinic.</td>
</tr>
<tr>
<td>15</td>
<td>Statistical mean value and standard error for antibacterials against <em>Neisseria gonorrhoeae</em>.</td>
</tr>
<tr>
<td>16</td>
<td>Synthesis of Biofilm by clinical isolates of <em>Candida</em> spp.</td>
</tr>
<tr>
<td>17</td>
<td>Production of Secretory Aspartyl Proteinase by the Clinical isolates of <em>Candida</em> spp.</td>
</tr>
<tr>
<td>18</td>
<td>Production of extracellular Phospholipase by <em>Candida</em> spp isolated from ICTC Clinic.</td>
</tr>
<tr>
<td>Table 19</td>
<td>Sensitivity / Resistant pattern of <em>Candida</em> spp to Hydrogen Peroxide.</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------------------------------------</td>
</tr>
<tr>
<td>Table 20</td>
<td>Hemolytic activity exhibited by <em>Candida</em> species isolated from ICTC Clinic</td>
</tr>
<tr>
<td>Table 21</td>
<td>The prevalence of azole resistance gene in multi drug resistance <em>Candida albicans</em></td>
</tr>
<tr>
<td>Table 22</td>
<td>Occurrence of Penicillinase Producing <em>Neisseria gonorrhoeae</em> (PPNG) plasmid obtained from clinical isolates of <em>Neisseria gonorrhoeae</em></td>
</tr>
<tr>
<td>Table 23</td>
<td>Occurrence of TRNG plasmid by PCR among the clinical isolates of <em>Neisseria gonorrhoeae</em></td>
</tr>
</tbody>
</table>
# LIST OF PLATES

<table>
<thead>
<tr>
<th>Plate</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Geographical location of the study area in Tamil Nadu</td>
</tr>
<tr>
<td>2</td>
<td>Cultural characterization of <em>Candida</em> spp and <em>Neisseria gonorrhoeae</em></td>
</tr>
<tr>
<td>3</td>
<td>Antibiogram of <em>Candida</em> spp</td>
</tr>
<tr>
<td>4</td>
<td>Antibiogram of <em>Neisseria gonorrhoeae</em></td>
</tr>
<tr>
<td>5</td>
<td>Virulence factors of <em>Candida</em> spp</td>
</tr>
<tr>
<td>6-10</td>
<td>Identification of CDR1 gene of <em>Candida albicans</em> by PCR</td>
</tr>
<tr>
<td>10-15</td>
<td>Identification of CDR2 gene of <em>Candida albicans</em> by PCR</td>
</tr>
<tr>
<td>15-20</td>
<td>Identification of MDR gene of <em>Candida albicans</em> by PCR</td>
</tr>
<tr>
<td>20-25</td>
<td>Identification of ERG11 gene of <em>Candida albicans</em> by PCR</td>
</tr>
<tr>
<td>26-29</td>
<td>Demonstration of PPNG Plasmid of <em>Neisseria gonorrhoeae</em></td>
</tr>
<tr>
<td>29-33</td>
<td>Demonstration of TRNG Plasmid of <em>Neisseria gonorrhoeae</em></td>
</tr>
<tr>
<td>34</td>
<td>Amplification of 28S rRNA gene of <em>Candida albicans</em> by PCR</td>
</tr>
<tr>
<td>35</td>
<td>28S rRNA sequences of <em>Candida albicans</em></td>
</tr>
<tr>
<td>36</td>
<td>BLAST analysis of 28SrRNA sequences of <em>Candida albicans</em></td>
</tr>
<tr>
<td>37</td>
<td>Similar search hits obtained through BLAST search</td>
</tr>
<tr>
<td>38</td>
<td>Amplification of tbpB gene of <em>Neisseria gonorrhoeae</em> by PCR</td>
</tr>
<tr>
<td>39</td>
<td>tbpB gene sequences of <em>Neisseria gonorrhoeae</em></td>
</tr>
<tr>
<td>40</td>
<td>BLAST analysis of tbpB gene of <em>Neisseria gonorrhoeae</em></td>
</tr>
<tr>
<td>41</td>
<td>Similar search hits obtained through BLAST search</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>ABC</td>
<td>ATP Binding Cassette</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired Immuno Deficiency Syndrome</td>
</tr>
<tr>
<td>ASGP-R</td>
<td>Asialo Glycoprotein Receptor</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine Tri Phosphate</td>
</tr>
<tr>
<td>CDC</td>
<td>Centre for Disease Control</td>
</tr>
<tr>
<td>CDR</td>
<td>Candida Drug Resistance</td>
</tr>
<tr>
<td>CEACAM</td>
<td>Carcino Embryonic Antigen-related family of Cell adhesion Molecules</td>
</tr>
<tr>
<td>CFU</td>
<td>Colony Forming Unit</td>
</tr>
<tr>
<td>CI</td>
<td>Class Interval</td>
</tr>
<tr>
<td>CMI</td>
<td>Cell Mediated Immunity</td>
</tr>
<tr>
<td>CMP</td>
<td>Cyclic Mono Phosphate</td>
</tr>
<tr>
<td>CR</td>
<td>Complement Receptor</td>
</tr>
<tr>
<td>DGI</td>
<td>Disseminated Gonococcal Infection</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribo Nucleic Acid</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylene Diamine Tetra Acetic acid</td>
</tr>
<tr>
<td>ERG</td>
<td>Ergosterol Resistance Gene</td>
</tr>
<tr>
<td>FTOC</td>
<td>Fallopian Tube Organ Culture</td>
</tr>
<tr>
<td>H$_2$O$_2$</td>
<td>Hydrogen peroxide</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B Virus</td>
</tr>
<tr>
<td>hCG</td>
<td>Human Chorio Gonadotrophic hormone</td>
</tr>
<tr>
<td>HCl</td>
<td>Hydro Chloride</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HPV</td>
<td>Human Papilloma Virus</td>
</tr>
<tr>
<td>HSPG</td>
<td>Heparin Sulfate Proteo Glycans</td>
</tr>
<tr>
<td>HSV</td>
<td>Herpes Simplex Virus</td>
</tr>
<tr>
<td>ICTC</td>
<td>Integrated Counselling and Testing Centre</td>
</tr>
</tbody>
</table>
IL-8 - Interleukin 8
IUCD - Intra Uterine Contraceptive Devices
IUD - Intra Uterine Devices
KCl - Potassium Chloride
KH$_2$PO$_4$ - Potassium Di Hydrogen Phosphate
KOH - Potassium Hydroxide
LHr - Lutropin receptor
LOS - Lipooligosaccharide
LPS - Lipopolysaccharide
MDa - Mega Daltons
MDR - Multi Drug Resistance
MFS - Major Facilitators Superfamily
µl - Microlitre
µg - Microgram
µm - Micrometer
mins - Minutes
mm - Millimeter
MgCl$_2$ - Magnesium Chloride
Na$_2$HPO$_4$ - Sodium Hydrogen Phosphate
NaCl - Sodium Chloride
NACO - National AIDS control organization
NCBI - National Center for Biotechnology Institute
NCCL - National Committee for Clinical Laboratory Standards
Opa - Opacity associated
OR - Odds Ratio
OTC - Over The Counter
PBS - Phosphate Buffer Saline
PCR - Polymerase Chain Reaction
PCR-RFLP - Polymerase Chain Reaction-Random Fragment Length Polymorphism
PHC - Primary Health Centre
PID - Pelvic Inflammatory Disease
PMN - Poly Morpho Nuclear
Por - Porin
PPNG - Penicillinase producing *Neisseria gonorrhoeae*
Rmp - Reduction modifiable protein
rRNA - Ribosomal ribonucleic acid
RTI - Reproductive Tract Infection
RVVC - Recurrent vulvovaginal candidiasis
SAP - Secreted Aspartyl Proteinase
SDA - Saboraud Dexrose Agar
SDS - Sodium Dodecyl Sulfate
STD - Sexually Transmitted Disease
STI - Sexually Transmitted Infection
TAE - Tris Acetic acid EDTA
TE - Tris EDTA
TNF-α - Tumour Necrosis Factor α
TRNG - Tetracycline Resistant *Neisseria gonorrhoeae*
UK - United Kingdom
US - United States
UV - Ultra Violet
VVC - Vulvovaginal Candidiasis
WHO - World Health Organization
YPD - Yeast Extract Peptone Dextrose medium